"Antiparkinson Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.
Concept/Terms
Antiparkinson Agents- Antiparkinson Agents
- Agents, Antiparkinson
- Antiparkinsonian Agents
- Agents, Antiparkinsonian
- Antiparkinsonians
- Antiparkinson Drugs
- Drugs, Antiparkinson
Below are MeSH descriptors whose meaning is more general than "Antiparkinson Agents".
Below are MeSH descriptors whose meaning is more specific than "Antiparkinson Agents".
This graph shows the total number of publications written about "Antiparkinson Agents" by people in Harvard Catalyst Profiles by year, and whether "Antiparkinson Agents" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 0 | 1 |
1996 | 2 | 1 | 3 |
1997 | 2 | 3 | 5 |
1998 | 3 | 0 | 3 |
1999 | 1 | 0 | 1 |
2000 | 1 | 0 | 1 |
2001 | 2 | 0 | 2 |
2002 | 2 | 2 | 4 |
2003 | 2 | 4 | 6 |
2004 | 2 | 2 | 4 |
2005 | 4 | 3 | 7 |
2006 | 4 | 2 | 6 |
2007 | 2 | 3 | 5 |
2008 | 0 | 1 | 1 |
2009 | 4 | 3 | 7 |
2010 | 2 | 4 | 6 |
2011 | 4 | 3 | 7 |
2012 | 5 | 2 | 7 |
2013 | 3 | 0 | 3 |
2014 | 2 | 2 | 4 |
2015 | 2 | 1 | 3 |
2016 | 4 | 1 | 5 |
2017 | 2 | 1 | 3 |
2018 | 3 | 3 | 6 |
2019 | 1 | 1 | 2 |
2020 | 3 | 2 | 5 |
2021 | 1 | 3 | 4 |
2022 | 1 | 1 | 2 |
2023 | 0 | 2 | 2 |
2024 | 1 | 1 | 2 |
Below are the most recent publications written about "Antiparkinson Agents" by people in Profiles.
-
OFF-times before, during, and after nighttime sleep periods in Parkinson's disease patients with motor fluctuations and the effects of opicapone: A post hoc analysis of diary data from BIPARK-1 and -2. Parkinsonism Relat Disord. 2024 Jun; 123:106971.
-
Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials Initiative. J Parkinsons Dis. 2024; 14(4):657-666.
-
Intrinsic auricular muscle zone stimulation for Parkinson disease: The EARSTIM-PD Phase II multi-center pilot study results. Parkinsonism Relat Disord. 2024 Apr; 121:105959.
-
Parkinson's disease - current treatment. Curr Opin Neurol. 2023 08 01; 36(4):302-308.
-
Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial. Trials. 2022 Oct 06; 23(1):855.
-
Trial of Cinpanemab in Early Parkinson's Disease. N Engl J Med. 2022 08 04; 387(5):408-420.
-
Opicapone for the Treatment of Parkinson's Disease "Off" Episodes: Pharmacology and Clinical Considerations. Clin Drug Investig. 2022 Feb; 42(2):127-135.
-
Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial. Neurology. 2022 01 04; 98(1):e40-e50.
-
A technology evaluation of CVT-301 (Inbrija): an inhalable therapy for treatment of Parkinson's disease. Expert Opin Drug Deliv. 2021 11; 18(11):1559-1569.
-
Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease: a meta-analysis. Neurol Sci. 2021 Aug; 42(8):3135-3143.